RemeGen Co., Ltd. entered into an exclusive license agreement with AbbVie for RC148, which became effective on March 10, 2026. Pursuant to the agreement, AbbVie would obtain exclusive rights to develop, manufacture and commercialize RC148 outside Greater China. In consideration, the Company would receive an USD 650 million upfront payment and is eligible to receive additional development, regulatory and commercial milestone payments of up to USD 4,950 million, as well as tiered double-digit royalty payments based on net sales of RC148 outside Greater China.
The Company has received the USD 650 million upfront payment from AbbVie (through its holding company) under the exclusive license agreement for RC148, a novel PD-1/VEGF targeting bispecific antibody drug independently developed by the Company. The collaboration between the two parties is progressing smoothly.
